Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-08-14
2007-08-14
Ungar, Susan (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C530S300000, C530S350000, C435S069100, C435S069700, C435S173300, C435S320100, C424S272100, C424S268100, C424S265100, C424S199100, C424S191100, C424S185100
Reexamination Certificate
active
10404667
ABSTRACT:
In this application is described the expression and purification of a recombinantPlasmodium falciparum(FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
REFERENCES:
patent: 4978621 (1990-12-01), Ardeshir et al.
patent: 6551586 (2003-04-01), Davidson et al.
patent: 2245727 (1997-08-01), None
patent: WO-01/34188 (2001-05-01), None
Stowers et al, Infection and Immunity 2001, 69:1536-1546.
Kumar, S. et al., 1995. Immunogenicity and in vivo efficacy of recombinantPlasmodium falciparummerozoite surface protein-1 inAotusmonkeys. Molecular Medicine 1, 325-332.
Kumar, S. et al., 2002. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 ofPlasmodium falciparuminduces antibody, interferon-γ and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. Immunology Letters 81, 13-24.
Angov, E. et al., 2003. Development and pre-clinical analysis of aPlasmodium faciparummerozoite surface protein-142malaria vaccine. Molecular & Biochemical Parasitology 128, 195-204.
Genton, B. et al., 2000. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18, 2504-2511.
Chang, S. P. et al., 1996. A recombinant baculovirus 42-kilodalton C-terminal fragment ofPlasmodium falciparummerozoite surface protein 1 protectsAotusmonkeys against malaria. Infection and Immunity 64, 253-261.
Genton, B. et al., 2002. A recombinant blood-stage malaria vaccine reducesPlasmodium falciparumdensity and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. of Infectious Diseases 185, 820-827.
Angov et al., “Process Development for Clinical GradePlasmodium falciparumMSP1/42 (3D7) Expressed inE. coli”, American Journal of Tropical Medicine & Hygiene, Lawrence, Nov. 28, 1999, p. 207, vol. 61, No. 3.
Dutta et al., “Purification, Characterization, and Immunogenicity of a Disulfide Cross-LinkedPlasmodium vivaxVaccine Candidate Antigen, Merozoite Surface Protein 1, Expressed inEscherichia coli”, Infection and Immunity, American Society for Microbiology, Sep. 2001, pp. 5464-5470, vol. 69, No. 9.
Pang et al., “In Vivo Expression and Immunological Studies of the 42-Kilodalton Carboxyl-Terminal Processing Fragment ofPlasmodium falciparumMerozoite Surface Protein 1 in the Baculovirus-Silkworm System”, Infection and Immunity, Jun. 2002, pp. 2772-2779, vol. 70, No. 6.
Qian et al., “Inducible Expression of MSP1 Gene ofPlasmodium falciparumby a Tetracycline-Controlled Promoter”, Chinese Journal of Parasitology & Parasitic Diseases, 2000, pp. 193-196, vol. 18, No. 4. (with English Abstract).
Weiqing et al., “Vaccine Candidate MSP-1 fromPlasmodium falciparum: a Redesigned 4917 BP Polynucleotide Enables Synthesis and Isolation of Full-Length Protein fromEscherichia coliand Mammalian Cells”, Nucleic Acids Research, 1999, pp. 1094-1103, vol. 27, No. 4.
Longacre, S., et al., Mol. Biochem. Parasitol. 64(2); 191-205, Apr. 1994.
Angov Evelina
Cohen Joe D.
Darko Christian Asare
Lyon Jeffrey A.
Arwine Elizabeth
Baskar Padma
GlaxoSmithKline Biologicals S.A.
Ungar Susan
United States of America as represented by the Secretary of the
LandOfFree
Recombinant P. falciparum merozoite protein-1 42 vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant P. falciparum merozoite protein-1 42 vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant P. falciparum merozoite protein-1 42 vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3864061